Activiomics Signs Research Agreement with Kyowa Hakko Kirin
Complete the form below to unlock access to ALL audio articles.
Activiomics has announced that it has signed a research agreement with the Japanese pharmaceutical company Kyowa Hakko Kirin.
Under the agreement, Activiomics will apply its novel TIQUAS phosphoproteomics platform to elucidate signalling mechanisms of lead compounds in relevant cell-based systems.
This agreement was signed as part of Activiomics’ recently announced strategic partnership with BioFocus.
Activiomics partners with Pharma and Biotech using its innovative mass spectrometry based methods to analyze and interpret cell signalling pathway activity, generating high value information for the pharmaceutical and biotechnology industry.
“We’ve engaged with Activiomics because we recognize that Activiomics’ label free phosphoproteomics approach can provide unique insights into signalling pathway activity, information that can complement and extend our existing gene expression datasets. This technology will enable us to better understand cell signalling mechanisms of our lead compounds and could enable us to identify important biomarkers” said Etsuo Ohshima, Ph.D., managing officer and vice president, head, research division at Kyowa Hakko Kirin.
Dr Neil Torbett, COO of Activiomics, said: “We are delighted to have signed this agreement with Kyowa Hakko Kirin. This is a further endorsement of our technology platform and also represents Activiomics’ first entry into the Japanese market. Activiomics has received invaluable support from BioFocus in establishing this collaboration, a clear demonstration of our strategic partnership in action”.
Dr Chris Newton, Managing Director of BioFocus, commented “BioFocus is pleased to have participated in the signing of this deal, which we intend to be the first of many. Future deals will add together BioFocus’ drug discovery capabilities and Activiomics’ phosphoproteomics platform for the furtherance of our clients’ projects”.
